Nurse Loses Drug-Prescribing Rights in Swift DEA Revocation
Published Date: 2/21/2025
Notice
Summary
Jason Weakley, a nurse practitioner, lost his DEA registrations for Vermont and New Hampshire because he no longer has permission to handle controlled substances in those states. He didn’t ask for a hearing to challenge this, so the DEA officially revoked his certificates. This means he can’t legally prescribe or manage controlled drugs in these states anymore, effective immediately.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
DEA Registrations Revoked; Renewals Denied
The DEA revoked Jason Weakley’s Certificates of Registration Nos. MW7073757 (Vermont) and MW7551460 (New Hampshire), so he cannot legally prescribe, dispense, or handle controlled substances in Vermont or New Hampshire. The Order also denies any pending applications to renew, modify, or obtain additional registration in those two states. The Order is effective March 24, 2025; the record shows his Vermont RN and APRN licenses were expired and suspended as of January 15, 2024, and his New Hampshire RN and APRN licenses expired March 23, 2024.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06051 — Importer of Controlled Substances Application: Usona Institute
Usona Institute wants to become an official importer of some powerful controlled substances like mescaline and psilocybin. People who make or use these drugs can share their thoughts or ask for a hearing by April 29, 2026. This move could impact research and medical use, with no direct cost changes announced yet.
2026-05912 — Bulk Manufacturer of Controlled Substances Application: SpecGx LLC
SpecGx LLC wants to become a big-time maker of some powerful and tightly controlled drugs, including things like psilocybin and fentanyl. People and companies already registered can share their thoughts or ask for a hearing by May 26, 2026. This move could shake up how these substances are made and handled, so keep an eye on the deadlines if you’re involved!
2026-05618 — Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I
Starting April 22, 2026, the DEA is putting 3-methoxyphencyclidine (3-MeO-PCP) into Schedule I, meaning it’s now officially a highly controlled substance with strict rules. This affects anyone who makes, sells, studies, or even possesses 3-MeO-PCP, who will face serious legal consequences. This move helps the U.S. follow international drug laws and keeps communities safer.
2026-05482 — Ordering Schedule I and II Controlled Substances Using DEA Form 222; Technical Amendments
If you order Schedule I or II drugs using DEA Form 222, this update clears up who can sign and manage the form—only registrants, their partners, or officers can do it. It also removes old rules about the old triplicate form, making things simpler and clearer. These fixes don’t change any big rules and take effect on March 20, 2026, so no extra costs or hassles ahead!
2026-05486 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) just updated which chemical mixes are officially exempt from strict drug rules between September 2024 and December 2025. Companies and labs using these chemicals should check the new list to see if their products are approved or denied. You’ve got until May 19, 2026, to share your thoughts, and no extra fees are involved—just a quick review and comment if you want!
2026-05359 — Importer of Controlled Substances Application: United States Pharmacopeial Convention
The United States Pharmacopeial Convention wants to become an official importer of certain controlled substances like Cathinone and Methcathinone. If you’re a registered manufacturer or interested party, you have until April 20, 2026, to share your thoughts or ask for a hearing. This move could impact how these substances are imported and tracked, but no direct costs are mentioned.
Previous / Next Documents
Previous: 2025-02935 — Combined Notice of Filings
The Federal Energy Regulatory Commission got new requests from natural gas companies to change pipeline rates and agreements starting as soon as February 1, 2025. These changes could affect how much customers pay or get refunded. If you want to speak up or get involved, you need to act by the listed deadlines in February and March.
Next: 2025-03023 — Sunshine Act Meetings
The National Council on Disability is holding a two-day meeting on March 6-7, 2025, both in Washington, DC, and online. They’ll discuss important topics like tax issues for disabled workers, disaster experiences, and ethics training, with a special chance for the public to share their thoughts. This meeting affects people with disabilities, advocates, and anyone interested in disability rights, with no new costs but plenty of fresh ideas and updates.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in